Serum Institute begins Phase I of experimental COVID-19 vaccine using Dynavax adjuvant

Serum Institute begins Phase I of experimental COVID-19 vaccine using Dynavax adjuvant The Phase 1 portion of the clinical trial will enroll 39 healthy volunteers and post the completion of the study a decision will be taken regarding the dosing of up to 216 subjects in Phase 2.

No comments:

Post a Comment